¤E¤Q¤E¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¸~½F¬ì

(B) 1. ¤@55·³¤k©Ê³Ìªñªº¨Ò¦æ¨Å©ÐX¥úÄá¼vÀˬdµo²{¥ª°¼¨Å©Ð²§±`¶t¤Æ¡C¦¹¯f¤H¹L¥h¨­Å骬ªp¨}¦n¡A¨ÃµL¨ä¥L¹L¥h¯f¥v¡A¦oªº«¼¶ý80·³¦]¨ÅÀù¦º¤`¡A§¹¾ãªº®a±Ú¥v¤¤¨ÃµL¨ä¥L®a±Ú¦¨­û¿©±w¨ÅÀù©Î§Z±_Àù¡C²z¾ÇÀˬd(¥]¬A¨Å©Ð»PµÅ¤U²O¤Úµ²Àˬd)¨ÃµL²§±`µo²{¡A¦å²G¹³¡B¦å²M¥Í¤Æ¡B§¿²G»P¯Ý³¡¢æ¥úÄá¼vµ¥Àˬd§¡¥¿±`¡C¯f¤H±µ¨ü¢æ¥ú¼v¹³¾É¤Þ²Ê°w¤Á¤ùÀˬd¡A³ø§i¬°«Iŧ©Ê¨ÅºÞ¸¢¸¢Àù(invasive ductal adenocarcinoma)¡A¦o±µ¨ü¨Å©Ð²§±`¶t¤Æ¤Á°£¡A»P¥ª°¼µÅ¤U«e­ï²O¤Úµ²(sentinel lymph node) ¤Á°£±Ä¼Ë¡C ¯f²zÀˬd½T»{¤@­Ó1.1¤½¤À¤j¤pªºinvasive ductal adenocarcinoma¡A¤â³NÃä½t°®²b¨ÃµL¸~½F«I¥Ç¡A¥B«e­ï²O¤Úµ²§¡¨S¦³Àù²Ó­MÂಾ«I¥Ç¡C¤U¦C³B¸m¡A¹ï¦¹¯f¤Hªº¥¼¨ÓªvÀø­p¹º³Ì¦³À°§U¡H
A.°l¥[¶i¦æ¥ª°¼µÅ¤U²O¤Úµ²¹ø²M¤â³N(radical lymph node dissection)
B.¯f²z²Õ´¬V¦âER (estrogen±µ¨üÅé)»PPR (progesterone±µ¨üÅé)ªºªí²{±¡§Î
C.¥þ¨­ªº¥¿¤l±½´yÄá¼v(18-FDG-PET scan)
D.BRCA1¬ðÅܪº°ò¦]ÀË´ú
E.BRCA2¬ðÅܪº°ò¦]ÀË´ú
 
(C) 2. ¤@70·³¨k©Ê¦³40 pack-yearªº©âµÒ¥v¡Aªñ¤T­Ó¤ë©I§l«æ«P´c¤Æ¨Ó¨D¶E¡C¥L±q¨Æ©ó¥Ûºø(asbestos)¥Ë¤u¤H¦³ªñ40¦~¾·~¥v¡C¯Ý³¡X¥úµo²{¥k°¼¤j¶q¦Ø½¤¿n¤ô¡A¦Ø½¤¿n¤ô©â§lÀˬdµo²{mesothelioma²Ó­M¡C¯ÝµÄ¹q¸£Â_¼h±½´yµo²{¤j½d³òÄjº©©Ê¥k°¼¦Ø½¤¼W«p¡AªÍªù»PÁa»JµÄ²O¤Úµ²¸~¤j¡A¦ý¨ÃµLªÍ¹ê½è¸~¶ô¡A¦Ø½¤¤Á¤ù¤]Ãҹꬰ¤W¥Ö²Ó­M«¬(epithelial-type) mesothelioma¡C¥LªºªÍ¥\¯à¤£¨}¡Aforced vital capacity (FVC)¶È¦³1.5¤É¡C¤U¦C¦óªÌ¬°¹ï¦¹¯f¤H³Ì«ê·íªºªvÀø¿ï¶µ¡H
A.¤â³N¸~½F¤Á°£extrapleural pneumonectomy¡A±µµÛµ¹¤©»²§U©Êcisplatin/ pemetrexed¤ÆÀø»P¯ÝµÄ©ñ®gªvÀø
B.¥ýµ¹¤©neoadjuvant·s»²§U©Êcisplatin/ pemetrexed¤ÆÀø»P¯ÝµÄ©ñ®gªvÀø¡A¦A±µ¨ü¤â³N¸~½F¤Á°£
C.±µ¨ücisplatin/ pemetrexed²Õ¦X¦¡¤Æ¾ÇªvÀø
D.±µ¨ücisplatin/ pemetrexed²Õ¦X¦¡¤ÆÀø¡A¨Ö¥Î¯ÝµÄ©ñ®gªvÀø
E.±µ¨ü¯ÝµÄ©ñ®gªvÀø
 
(C) 3. ·í¨Ï¥Î¤W¥Ö¥Íªø¦]¤l±µ¨üÅéEGFR³æ®è§ÜÅé(cetuximab©Îpanitumumab monoclonal antibody)§@¬°¥Íª«©Êªv¾¯¨ÓªvÀøÂಾ©Êµ²ª½¸zÀù¡A¸Ó³æ®è§ÜÅ馳ª½±µ§Ü¸~½F¼W¥Í®ÄªG(direct anti-proliferative effect)¡C¤U¦C¦óºØ¹êÅç«ÇÀË´ú¤wª¾¥i¥Î©ó¹w´úªvÀø¤ÏÀ³¡H¦¹¹êÅç«ÇÀË´ú¥iµø¬°¹w´ú©Êªº¥Íª«¼Ð°O(predictive biomarker)¡C
A.Treg levels
B.¦å²MIL-10 levels
C.KRAS¬ðÅÜ
D.¸~½FCD52
E.EGFR¬ðÅÜ
 
(C) 4. ¤@47·³¨k©Ê¦]¥k°¼ÀV³¡¸~¶ô¦³2­Ó¤ë¦Ó¨Ó¨D¶E¡A²Ó°w¬ï¨ëÀˬdµo²{Å쪬¤W¥Ö²Ó­MÀù(squamous cell carcinoma)¡AÀYÀV³¡¹q¸£Â_¼hÀˬdµo²{¥k°¼tonsil¤£¹ïºÙ¸~¶ô¡A¦X¨Ö¦³¥k°¼ÀV³¡²O¤Úµ²¸~¤j(level 2»Plevel 3)¡A¥L±µ¨ü¥k°¼tonsillectomy¤â³N¤Á°£»P¥kÀV¿ï¾Ü©Ê²O¤Úµ²¹ø²M³N(selective neck dissection)¡C¯f²z³ø§iÅã¥Ü¥k°¼tonsil¬°¤j¤p3.5¤½¤Àªºsquamous cell carcinoma¡A²`³¡¤â³NÃä½t¶È¤£¨ì1mm¡A¦P°¼¦h­Ó²O¤Úµ²¤w«I¥Ç¡A¥B¤w¦³²O¤Úµ²²ó½¤¥~«I¥Ç(capsular invasion)¡A¨Ã¥¼¨£¯«¸g©P³ò©Î¦åºÞ¤º«I¥Ç¡C¿Ã¥ú­ì¦ìÂø¦Xªk(FISH)Àˬdµo²{¤HÃþ¨ÅÀY¯f¬r(HPV)²Ä16«¬¶§©Ê¡C¤U¦C¶i¤@¨BªvÀø­pµe¦óªÌ³Ì¬°¦X¾A¡H
A.¦]HPV¶§©Ê¡A¹w«á¨}¦n¡AµL»Ý¶i¤@¨BªvÀø
B.¹ï­ìµo³¡¦ì¦A¦¸¤â³N(re-resection)¡A¥H¹F¨ì¸û¥R¨¬©Î¼e¼sªº³±©Ê¤â³NÃä½t(negative margin)
C.»²§U©Ê(adjuvant) cisplatin¤Æ¾ÇªvÀø¦P¨B¨Ö¥Î°w¹ï­ìµo³¡¦ì»P¦P°¼ÀV³¡¤§©ñ®gÀøªk
D.°w¹ï­ìµo³¡¦ì»P¦P°¼ÀV³¡¡Aµ¹¤©»²§U©Ê©ñ®gÀøªk70Gy
E.°w¹ï¦P°¼ÀV³¡¡Aµ¹¤©»²§U©Ê©ñ®gÀøªk70Gy
 
(D) 5. ¤@75·³¨k©Ê¿©±wÄáÅ@¸¢Àù¦X¨Ö°©ÀfÂಾ»P¯kµh¡C¦å¬õ¯ÀÀˬd¬°10.5 g/dL¡A§Ü²üº¸»XªvÀø«eªºPSA¬°1860 ng/mL¡C¥L±µ¨ü¨k©Ê²üº¸»X­ç°£ªvÀø(androgen ablation)¡A¨Ï¥Îgoserelin(ªø®Ä«¬gonadotropin releasing hormone, GnRH, analog)¨Ö¥Îbicalutamide(§Ü¨k©Ê²üº¸»Xantiandrogen»s¾¯)¡A6­Ó¤ë«á¡A¯kµh¯gª¬¤wÅãµÛ½w¸Ñ¡A¥BPSA¼Æ­È¤w­°¦Ü0.1 ng/mL¡A¯f¤H«ùÄòªvÀø¥B¨C3­Ó¤ëÀË´úPSA¡C¦ÜªvÀø18­Ó¤ë®É¡APSA¬ðµM¤W¤É¦Ü15 ng/mL¡A­«´úPSA½T»{¤W¤É¦Ü20 ng/mL¡A¦ý¨ä¥LÁ{§É»P©â¦å«ü¼Ð¨ÃµLÅܤơA¸A©Tà¬(testosterone)¼Æ­È¤´¦³®Ä¨ü¨ì§í¨îat castrated level¡CÂå®v³Ìªñ¤w¶}©l¨Ï¥ÎÂùÁC»ÄÆQbisphosphonateªvÀø¡Aºò±µ¤U¤@¨B§A«Øij±Ä¥Î¦óºØªvÀøµ¦²¤¡H
A.§ó´«¥t¤@ºØ§Ü¨k©Ê²üº¸»Xªv¾¯antiandrogen
B.¨Ï¥Îketoconazole¨Ö¥Îhydrocortisone
C.§ó´«¥t¤@ºØÂùÁC»ÄÆQbisphosphonateªv¾¯
D.¥ý°±¥Îbicalutamide¡A¦ýÄ~Äò¥ÎgoserelinªvÀø
E.¥ý¥ÎStronium-89©ñ®g¦P¦ì¯ÀªvÀø
 
(C) 6. ¤@47·³¤k©Ê¦]©Ê¦æ¬°«á(post-coital)¥X¦å¦Ó¨D¶E¡A°©¬ÖµÄÀˬd¥i¨£¤l®cÀV¦³¤@¢µ¤½¤À¸~¶ô¡A¤Á¤ùÃҹꬰÅ쪬¤W¥Ö²Ó­MÀù(squamous cell carcinoma)¡A¶i¤@¨B°©¬ÖµÄÀˬdÃÒ¹ê¸~½F¤w½T©w½¯©µ«I¥Ç¦Ü¥ª°©¬ÖµÄ°¼¾À(side wall)¡A¹q¸£Â_¼hCT±½´y¨ÃµL»·¹j¾¹©xÂಾ¡C¥H¤UªvÀø­pµe¦óªÌ³Ì¬°¾A·í¡H
A.®Ú°£©Ê¤l®c¤Á°£³Nradical hysterectomy¡A³N«áµ¹¤©°©¬Ö¤j½d³ò©ñ®gªvÀø¨Ö¥Î¦P¨Bcisplatin¤Æ¾ÇªvÀø
B.¥ýµ¹¤©°©¬ÖµÄ©ñ®gªvÀø¡A¤§«á¶i¦æpaclitaxel¥[carboplatin¤Æ¾ÇªvÀø
C.°©¬ÖµÄ¤j½d³ò©ñ®gªvÀø¨Ö¥Î¦P¨Bcisplatin¬°¥Dªº¤Æ¾ÇªvÀø
D.¥u¹ï¤l®cÀV¥X¦å³¡¦ìµ¹¤©§½³¡ªvÀø¡A¨Ãµ¹¤©¨ä¥L¤ä«ù©Ê¯gª¬Àøªk
E.®Ú°£©Ê¤l®c¤Á°£³Nradical hysterectomy
 
(B) 7. ¤@40·³¥xÆW¤k©Ê¯f¤H¡A¨ÃµL©âµÒ¥v¡A³Ìªñ³Q¶EÂ_¿©±w²ÄIV´ÁÂಾ©ÊªÍ¸¢Àù(adenocarcinoma)¡A¸~½Fªº°ò¦]ÀË´úµo²{¦³¤W¥Ö¥Íªø¦]¤l±µ¨üÅéEGFR²Ä21¥~Âà¤l(exon 21)¬ðÅÜ¡C½Ð°Ý¤U¦C¦óºØªvÀø³Ì¬°¾A·í¡H
A.Gefitinib¨Ö¥ÎChemotherapy
B.Gefitinib
C.Bevacizumab
D.Gefitinib¨Ö¥ÎBevacizumab
E.Cetuximab
 
(B) 8. ¤@45·³¨k©Ê¦]±Æ«K¤¤±a¦å»P¸Ñ«K«áùØ«æ«á­«·P(tenesmus)¨Ó¨D¶E¡A¥D¶DÅãµÛ¸¡µÈ·P»P±Æ«K§xÃø¤w¦³¤@­Ó¤ë¥ª¥k¡C¤j¸z¤ºµøÃè¥i¨£anal verge¤W¤è4¤½¤À¦³¤j«¬¸~¶ô¡A¥B¤ºµøÃè¤w¸gÃø¥H³q¹L¡A¤Á¤ùÃҹꬰadenocarcinoma¡C¹q¸£Â_¼h±½´yµo²{¦³¶W¹L10­Ó¥H¤Wªº¨xÂಾ¸~¶ô¡A¥B¦û¾Ú¤F¤j½d³ò¨xŦ¡A¦å²MAST¡BALT¡BALP§¡¤W¤É¬ù¥¿±`¤W­­ªº3­¿¡C«Øij¦óºØªvÀø³B¸m³Ì¬°¾A·í¡H
A.ª½±µ¶}©l¤ÆÀøoxaliplatin¡B5FU¡Bleucovorin
B.¥ý¬I¦æµ²¸z³y¤f³Ndiverting colostomy¡A¦A¶i¦æ²Õ¦X¦¡½Æ¤è¤Æ¾ÇªvÀø
C.¥ý¶i¦æ¸~½F¤Á°£¤â³Nabdominoperineal resection (APR)¡A¦A¶i¦æ¤Æ¾ÇªvÀø
D.¥ý¶i¦æ5FU¦P¨B¤ÆÀø©ñ®gÀøªk¡A¦A¶i¦æ¤Æ¾ÇªvÀøirinotecan¡B5FU¡Bleucovorin
E.¶i¦æ¸~½F¤Á°£¤â³Nabdominoperineal resection (APR)
 
(C) 9. ¦³Ãö­¹¹DÀù¤§¦P¨B©ñÀø¤ÆÀø¡]concurrent chemoradiotherapy¡^¡A¤U¦C±Ô­z¦óªÌ¬°¯u¡H1. ¨Ï¥Î5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡A¤j­P¥i¹F¯f²z§¹¥þ½w¸Ñ²v(pathologic complete response¡^¬ù15-30%¡C 2. ¥Hpaclitaxel©Îirinotecan¬°¥Dªº¤ÆÀø¨Ö¥Î©ñ®gÀøªk¡A¥H½w¸Ñ²v»P¦s¬¡´Á¦Ó¨¥¡Aµ²ªGÀu©ó5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡C3.¥Hpaclitaxel¬°¥Dªº¤ÆÀø¨Ö¥Î©ñ®gÀøªk¡A­G¸z¹Dªº¬ÛÃö¬r©Ê§C©ó5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡C4.©Ò¦³¯f¤H¦b±µ¨ü¦P¨B©ñÀø¤ÆÀø«e¡A§¡»Ý¸m©ñ­G¸zÁý­¹ºÞ(»ó­GºÞ¡B­G³y¤f¡BªÅ¸z³y¤fµ¥)¡C (½Ð¿ï¥X©Ò¦³¥¿½Tµª®×)
A.±Ô­z2»P3¬°¯u
B.±Ô­z1»P4¬°¯u
C.±Ô­z1»P3¬°¯u
D.±Ô­z1¡B2¡B3¡B4§¡¬°¯u
E.¥H¤W¬Ò«D
 
(D) 10. ¦³Ãö¯ØŦ¸¢Àù¡]adenocarcinoma of pancreas¡^¡A¦b±µ¨üªvÀø¥Ø¼Ð¬°®Úªv©Ê¡]curative¡^¤â³N¤Á°£pancreaticoduodenectomy¤§«á¡A¤U¦C±Ô­z¦óªÌ¬°¯u¡H
A.¤´¦³¬ù50%¥H¤W¯f¤H·|¦³§½³¡°Ï°ì©Ê´_µo
B.¯ØŦ¸¢Àù³æ¥Hpancreaticoduodenectomy¤â³N¤Á°£«á°lÂÜ¡A5¦~¾ãÅé¦s¬¡²v¤´¶È¬ù15-20%©Î§ó§C
C.¤â³N«á¥D­n¥HÂಾ¦Ü¸¡½¤»P¨xŦ¬°¥D¡A§½³¡´_µo¤Ö¨£
D.A»PB¬°¯u
E.B»PC¬°¯u
 


< ¤E¤Q¤E¦~«×¸ÕÃD¥Ø¿ý >